earnings
confidence high
sentiment positive
materiality 0.65
MiMedx Q3 net sales $84M (+3% YoY); raises FY2024 growth outlook to high single-digits
MIMEDX GROUP, INC.
2024-Q3 EPS reported
$0.23
revenue$255,972,000
- GAAP net income $8.1M ($0.05 EPS); Adjusted EBITDA $18.2M (21.6% margin), up from $17.6M a year ago.
- Cash and cash equivalents $89M; net cash position $70M, up $20M sequentially.
- 2024 net sales growth guidance raised to high single-digits (from mid-to-high single-digits); Adjusted EBITDA margin expected above 20%.
- Q3 gross margin 81.8% vs 81.9% prior year; growth driven by AMNIOEFFECT, EPIEFFECT and HELIOGEN products.